| Outcome Measures: |
Primary: Renal composite outcome, Renal composite outcome would be defined as one of followings: 1. A sustained decline in eGFR of 40%, 2. Initiation of kidney replacement therapy (dialysis or kidney transplantation), 3. A sustained eGFR \<10 mL/min/1.73 m2, or 4. Death from renal causes, up to 3 years | Secondary: Individual components of renal composite outcome, 1. A sustained decline in eGFR of 40% 2. Initiation of kidney replacement therapy (dialysis or kidney transplantation), 3. A sustained eGFR \<10 mL/min/1.73 m2 4. Death from renal causes 5. Rate of change of eGFR during chronic phase I (12 week to 3 year) 6. Rate of change of eGFR during chronic phase II (24 week to 3 year) 7. Rate of change of eGFR during study period (0 week to 3 year) 8. Cardiovascular composite outcome (defined as one of followings): 1. Death from cardiovascular causes, 2. Non-fatal myocardial infarction, 3. Non-fatal stroke (ischemic or hemorrhagic), 4. Hospitalization for heart failure, or 5. Revascularization (coronary, carotid, or peripheral artery), up to 3 years|eGFR slopes, 1. A sustained decline in eGFR of 40% 2. Initiation of kidney replacement therapy (dialysis or kidney transplantation), 3. A sustained eGFR \<10 mL/min/1.73 m2 4. Death from renal causes 5. Rate of change of eGFR during chronic phase I (12 week to 3 year) 6. Rate of change of eGFR during chronic phase II (24 week to 3 year) 7. Rate of change of eGFR during study period (0 week to 3 year) 8. Cardiovascular composite outcome (defined as one of followings): 1. Death from cardiovascular causes, 2. Non-fatal myocardial infarction, 3. Non-fatal stroke (ischemic or hemorrhagic), 4. Hospitalization for heart failure, or 5. Revascularization (coronary, carotid, or peripheral artery), up to 3 years|Cardiovascular composite outcome, 1. A sustained decline in eGFR of 40% 2. Initiation of kidney replacement therapy (dialysis or kidney transplantation), 3. A sustained eGFR \<10 mL/min/1.73 m2 4. Death from renal causes 5. Rate of change of eGFR during chronic phase I (12 week to 3 year) 6. Rate of change of eGFR during chronic phase II (24 week to 3 year) 7. Rate of change of eGFR during study period (0 week to 3 year) 8. Cardiovascular composite outcome (defined as one of followings): 1. Death from cardiovascular causes, 2. Non-fatal myocardial infarction, 3. Non-fatal stroke (ischemic or hemorrhagic), 4. Hospitalization for heart failure, or 5. Revascularization (coronary, carotid, or peripheral artery), up to 3 years
|
